百特醫療 (BAX) 2019 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to the Baxter International Third Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2019 年第三季財報電話會議。(接線員指示)提醒各位,本通話由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請立即掛線。

  • I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Thanks, Catherine. Good morning, and welcome to our third quarter 2019 conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.

    謝謝你,Catherine。各位早安,歡迎參加我們 2019 年第三季電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。

  • As you saw in today's press release, the company recently initiated an internal investigation into misstatements in our previously reported nonoperating income related to foreign exchange gains and losses. While the investigation is ongoing, we are not able to provide full financial results and will be focusing today's call on preliminary operating results for the third quarter of 2019. As such, we will not be commenting on any financial measures other than those above the operating income line for the third quarter or any future period.

    如各位在今日新聞稿中所見,公司近期就先前所揭露、與外匯損益相關的非營業收入之錯誤陳述,啟動了一項內部調查。由於調查仍在進行中,我們目前無法提供完整財務結果,今天的電話會議將聚焦於 2019 年第三季的初步營運結果。因此,我們不會就第三季或任何未來期間、除營業利益線以上的任何財務衡量指標發表評論。

  • A supplemental presentation to complement this morning's discussion can be accessed on our website. This presentation includes related non-GAAP reconciliations and can be accessed on Baxter's external website in the Investors section under Events & News.

    可於我們網站取得補充簡報,以配合今天上午的討論。該簡報包含相關的非 GAAP 調節表,可在百特對外網站「投資人」專區的「活動與新聞」項下取得。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters, contain forward-looking statements that involve risks and uncertainties, and of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.

    接下來,在開始我們的準備發言前,先提醒各位,本簡報(包括關於我們財務展望、新產品開發、業務發展及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性;當然,我們的實際結果可能與目前預期有重大差異。請參閱今日新聞稿及我們向 SEC 提交的文件,以了解可能導致實際結果與預期有重大差異之因素的更多細節。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our preliminary operating results press release issued this morning and is available on our website within our investor presentation.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性的業務表現。今日討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布的初步營運結果新聞稿中,並可在我們網站的投資人簡報中取得。

  • On the call this morning, we will be discussing operational sales growth, which adjusts for the impact of foreign exchange and generic competition for cyclophosphamide in the U.S.

    在今天上午的電話會議中,我們將討論營運銷售成長(operational sales growth),其已調整外匯影響以及美國市場環磷醯胺(cyclophosphamide)之學名藥競爭影響。

  • Now I'd like to turn the call over to Joe. Joe?

    現在我想把電話交給 Joe。Joe?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Thanks, Clare. And before we get into a discussion regarding our third quarter performance, I want to address the ongoing internal investigation that we disclosed in today's press release. First, I want to emphasize that our Board and leadership teams are taking this matter very seriously. Baxter recently begun an internal investigation assisted by experienced outside investors (sic) [advisers] into misstatements in our previously reported nonoperating income related to foreign exchange gains and losses. These misstatements were in part a result of the company's historical use of a foreign exchange rate convention that was not consistent with GAAP. Our Board's Audit Committee is overseeing the investigation with the assistance of independent experienced external advisers. We voluntarily advised the SEC that the internal investigation is underway and intend to provide them with additional information as the investigation progresses. The investigation is in its early stages, and we cannot predict its duration or outcome.

    謝謝你,Clare。在我們開始討論第三季表現之前,我想先談談我們在今日新聞稿中揭露、目前仍在進行的內部調查。首先,我要強調,我們的董事會與管理團隊非常嚴肅看待此事。百特近期已展開內部調查,並在具經驗的外部投資人(原文如此)[顧問]協助下,針對先前所報導、與外匯損益相關的非營業收入之錯誤陳述進行調查。這些錯誤陳述部分源於公司歷來使用的一項外匯匯率慣例,與 GAAP 不一致。董事會審計委員會在具經驗且獨立的外部顧問協助下監督本次調查。我們已主動告知 SEC 內部調查正在進行,並將隨調查進展提供更多資訊。調查仍處於初期階段,我們無法預測其持續時間或結果。

  • As a result, we do not expect to file a quarterly report on Form 10-Q for the period ended September 30, 2019, on a timely basis. Upon completion of the investigation, our evaluation of the materiality of the misstatements, we expect to either amend our periodic reports previously filed with the SEC to include restated financial statements that correct those misstatements or include in reports for future periods restated comparative financial statements that correct those misstatements.

    因此,我們預期無法在期限內提交截至 2019 年 9 月 30 日止期間的 Form 10-Q 季報。在調查完成並評估錯誤陳述之重大性後,我們預期將採取以下其中一項作法:修正先前已向 SEC 提交的定期報告,納入更正該等錯誤陳述之重編財務報表;或在未來期間的報告中納入更正該等錯誤陳述之重編比較財務報表。

  • As part of any corrections to previously issued financial statements after completion of the nonoperating income investigation, Baxter also expects to correct certain operational items that were immaterial to its previously reported results of operations. These items include impact of the use of the foreign exchange rate convention to translate the results of the company's foreign operations into U.S. dollars and the impact of the incorrect accounting for placed equipment that the company leases to its customers.

    作為在非營業收入調查完成後對先前已發布財務報表所作任何更正的一部分,百特亦預期將更正若干對先前所報導營運結果並不重大之營運項目。這些項目包括:使用該外匯匯率慣例將公司海外營運結果換算為美元之影響,以及對公司出租予客戶之投放設備(placed equipment)採用不正確會計處理之影響。

  • Across Baxter, we're taking steps to strengthen and enhance our internal controls and look forward to sharing our full financial results as soon as it is appropriate. We will continue to execute against our business strategies targeted to deliver top-quartile industry performance. And our 50,000 employees remain focused on building our positive momentum and maintaining ethics and compliance in everything we do.

    在百特全公司範圍內,我們正採取措施強化並提升內部控制,並期待在適當時機盡快分享完整財務結果。我們將持續執行業務策略,目標是交出業界前四分位的表現。我們 50,000 名員工仍專注於延續正向動能,並在所有工作中維持道德與法遵。

  • Please note that there isn't additional detail regarding investigation that we can share beyond what we have provided in our press release. We therefore ask that your questions during the Q&A portion of this call be focused on our preliminary operating results, business progress and innovation efforts.

    請注意,除我們在新聞稿中提供的內容外,關於本次調查我們沒有其他可分享的細節。因此,我們請各位在本次電話會議的問答環節中,將問題聚焦於我們的初步營運結果、業務進展與創新工作。

  • With that, I will now turn the call over to Jay.

    接下來,我把電話交給 Jay。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Thanks, Joe, and good morning, everyone. Our third quarter results reflect strong performance across our 3 geographic segments and all 6 Global Business Units. Given the ongoing internal investigation, we are not able to provide year-over-year comparisons for segments and Global Business Units but will speak to the specific drivers of performance in the quarter.

    謝謝你,Joe,各位早安。我們第三季的結果反映出在三大地理區隔與六大全球事業單位的強勁表現。鑑於內部調查仍在進行中,我們無法提供各區隔與全球事業單位的年對年比較,但會說明本季表現的具體驅動因素。

  • In the third quarter, global sales of $2.85 billion increased 3% on a reported basis and 5% on both a constant currency and operational basis, reflecting strength across our diversified portfolio. Adjusted operating margin of 19.5% was driven by our solid top line performance and ongoing operational efficiencies.

    第三季全球銷售額為 28.5 億美元,按報告基礎成長 3%,按固定匯率與營運基礎皆成長 5%,反映我們多元化產品組合的全面強勁表現。調整後營業利益率為 19.5%,主要受惠於穩健的營收表現與持續的營運效率提升。

  • Now I'll walk you through performance by our geographic segments and global businesses. Starting first with our 3 geographic segments. Sales in the Americas totaled $1.5 billion, sales in EMEA totaled $730 million, and sales in our Asia Pacific region totaled $587 million.

    接下來我將帶各位檢視各地理區隔與全球業務的表現。先從三大地理區隔開始。美洲地區銷售額合計 15 億美元,EMEA 地區銷售額合計 7.30 億美元,亞太地區銷售額合計 5.87 億美元。

  • Moving to performance by global businesses. Global sales for Renal Care were $918 million. Performance in the quarter was driven by strength in PD therapies globally with patient volumes advancing approximately 7% year-over-year and representing the highest quarterly patient volume growth year-to-date. Partially offsetting this was lower sales of select in-center HD products, including the bloodlines business exited earlier this year, which negatively impacted sales in the quarter by approximately $18 million.

    接著看各全球業務的表現。腎臟照護(Renal Care)全球銷售額為 9.18 億美元。本季表現主要由全球腹膜透析(PD)治療的強勁需求所帶動,病患量年對年成長約 7%,並創下今年迄今最高的單季病患量成長。部分抵銷因素為特定院內血液透析(HD)產品銷售下滑,包括我們今年稍早退出的血路(bloodlines)業務,對本季銷售造成約 1,800 萬美元的負面影響。

  • Renal Care sales were also impacted by the temporary supply constraints associated with the Revaclear dialyzer. The impact was less than $10 million in the quarter.

    腎臟照護銷售亦受到與 Revaclear 透析器相關的暫時性供應限制影響。本季影響低於 1,000 萬美元。

  • Sales in Medication Delivery of $701 million represented the focused commercial execution of our U.S. Hospital Products team. Performance in the quarter benefited from strong sales of Spectrum IQ Infusion System in the U.S. where we continue to increase our installed base of pumps and also from improved sales of small- and large-volume IV solutions globally as we continue to build momentum. We are pleased with the ongoing improvement in the business, particularly in the United States.

    藥物輸送(Medication Delivery)銷售額為 7.01 億美元,反映我們美國醫院產品團隊聚焦且到位的商業執行。本季表現受惠於 Spectrum IQ 輸注系統在美國的強勁銷售,我們持續擴大幫浦裝機基礎;同時,隨著我們持續累積動能,小容量與大容量靜脈輸液(IV)溶液在全球的銷售亦有所改善。我們對該業務持續改善感到滿意,尤其是在美國市場。

  • Pharmaceuticals sales were $527 million in the quarter. Contributing to performance in the quarter was robust demand for our international hospital pharmacy compounding services as well as increased sales of certain generic injectables. Partially offsetting these results were lower sales of anesthesia and critical care products as well as BREVIBLOC. Due to increased generic competition, U.S. cyclophosphamide sales totaled $41 million in the quarter.

    本季製藥業務銷售額為5.27億美元。本季表現的貢獻因素包括我們國際醫院藥局調配服務需求強勁,以及部分學名注射劑銷售增加。部分抵銷上述成果的是麻醉與重症照護產品以及BREVIBLOC的銷售下滑。由於學名藥競爭加劇,本季美國環磷醯胺銷售額合計為4,100萬美元。

  • Moving to Nutrition. Total sales were $219 million driven by improved sales of multi-chamber bags and micronutrients globally. International demand for automated nutrition compounding also contributed to performance in the quarter. Third quarter sales reflect the efforts taken to rebuild our U.S. business coupled with our focus on new product launch execution.

    接著談營養業務。總銷售額為2.19億美元,主要由全球多腔袋與微量營養素銷售改善所帶動。國際市場對自動化營養調配的需求也對本季表現有所貢獻。第三季銷售反映了我們為重建美國業務所採取的努力,以及我們對新產品上市執行的聚焦。

  • Total Advanced Surgery sales were $216 million in the quarter. Performance was driven by strength in hemostats and sealants, which benefited by more than $10 million in sales related to previously discussed competitive supply constraints, which are not expected to continue contributing at this level.

    本季先進外科(Advanced Surgery)總銷售額為2.16億美元。表現主要由止血劑與封合劑的強勁需求所帶動;其受惠於先前提及的競品供應受限所帶來逾1,000萬美元的相關銷售,但預期不會以此水準持續貢獻。

  • Third quarter sales in our Acute Therapies business of $130 million were driven by increased global demand for Baxter's continuous renal replacement therapies supported by the launch of new products, including PrisMax, Baxter's next-generation CRRT system.

    第三季我們急性治療(Acute Therapies)業務銷售額為1.30億美元,主要由全球對百特連續性腎臟替代治療(CRRT)需求增加所帶動,並受新產品上市支持,包括PrisMax——百特新一代CRRT系統。

  • Finally, sales in our other category, which primarily includes our contract manufacturing services, were $140 million in the quarter.

    最後,我們其他類別(主要包含委託製造服務)的本季銷售額為1.40億美元。

  • Moving through the rest of the P&L. Our adjusted gross margin of 45.7% benefited from strong top line performance as well as positive manufacturing variances. Issues associated with our dialyzer supply constraint negatively impacted gross profit by approximately $15 million in the quarter.

    接著看損益表其餘項目。我們調整後毛利率為45.7%,受惠於強勁的營收表現以及正向的製造差異。與透析器供應受限相關的問題在本季對毛利造成約1,500萬美元的負面影響。

  • Adjusted SG&A totaled $614 million as we strategically reinvest savings in general and administrative expenses to support our sales and marketing initiatives while maintaining our disciplined focus on managing discretionary expenses.

    調整後銷售、一般及行政費用(SG&A)合計為6.14億美元;我們策略性地將一般與行政費用節省下來的金額再投資,以支持銷售與行銷計畫,同時維持對可裁量性費用管理的紀律性聚焦。

  • Adjusted R&D spend in the quarter was $134 million. We continue to fund our new product development programs to deliver on our innovation pipeline while also realizing benefits from our ongoing optimization initiatives to optimize our R&D processes and the organization.

    本季調整後研發(R&D)支出為1.34億美元。我們持續投入新產品開發計畫以兌現創新產品管線,同時也從持續的最佳化計畫中受益,以優化研發流程與組織。

  • Adjusted operating margin in the quarter was 19.5% due to strong top line performance, manufacturing efficiencies and ongoing efforts to improve operational effectiveness across the company.

    本季調整後營業利益率為19.5%,主要因營收表現強勁、製造效率提升,以及公司持續推動改善營運效能的努力。

  • Let me conclude by commenting on the sales and adjusted operating margin outlook for the fourth quarter of 2019. We remain confident in the health of our business and in the strength of our commercial execution. Given the ongoing investigation, we are providing limited guidance for the remainder of the year. Specific to the fourth quarter of 2019, we expect sales growth of 3% to 4% on a reported basis and approximately 5% on both a constant currency and operational basis. We expect operating margin to be between 15.2% and 15.9% on a reported basis and between 18.5% and 19% on an adjusted basis.

    最後我就2019年第四季的銷售與調整後營業利益率展望做個說明。我們對業務的健康狀況以及商業執行力的強度仍具信心。鑑於調查仍在進行中,我們對今年剩餘期間提供有限的指引。就2019年第四季而言,我們預期以報告基礎計算的銷售成長為3%至4%,以固定匯率與營運基礎計算約為5%。我們預期以報告基礎計算的營業利益率介於15.2%至15.9%,以調整後基礎計算介於18.5%至19%。

  • Finally, I want to comment on our 2020 outlook. We're currently in the process of completing our annual operating plan. And as part of that activity, we're considering several factors and their potential impacts. Some of these items include the proposed Advancing American Kidney Health initiative and the related capital investments to support this, along with other government renal policy initiatives; capital investments and operational improvements we are making to enhance our quality and manufacturing capabilities; and the finalization of our agreements with various GPOs and IDNs in our U.S. Hospital Products business. As a result, it is premature to comment on 2020 guidance and beyond but anticipate providing more detail on our next earnings call.

    最後,我想談談我們對2020年的展望。我們目前正在完成年度營運計畫。作為該項工作的一部分,我們正在考量多項因素及其潛在影響。其中包括:擬議中的「推進美國腎臟健康(Advancing American Kidney Health)」倡議及為支持該倡議所需的相關資本投資,以及其他政府腎臟政策倡議;我們為提升品質與製造能力所進行的資本投資與營運改善;以及我們美國醫院產品業務與各家GPO與IDN之協議的最終定案。因此,現在就2020年及之後的指引發表評論仍為時過早,但我們預期在下一次財報電話會議提供更多細節。

  • With that, I'd like to turn the call back over to Joe.

    接下來,我想把電話交回給Joe。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • As Jay shared, our strategic transformation yielded positive performance across all of our business units and regions in the third quarter. The fundamental health of our business remains strong and reflects our growing momentum. We are continuing to drive operational excellence, strategically deploy capital to create shareholder value and advance compelling innovation in our core areas and effective adjacencies both through robust internal research and development and strategic business development.

    如Jay所分享,我們的策略轉型在第三季於所有事業單位與各地區均帶來正向表現。我們業務的基本面健康狀況仍然強勁,並反映出我們日益增強的動能。我們持續推動卓越營運,策略性地配置資本以創造股東價值,並在核心領域與有效的相鄰領域推進具吸引力的創新,這些創新同時透過強健的內部研發與策略性業務開發來實現。

  • In Renal Care, for example, we continue to believe the Advancing American Kidney Health initiative will offer tremendous benefits to patients with home dialysis embraced as a frontline option. We also continue to nurture our innovation pipeline in this space, including advancements in early-stage technology that could have a transformative impact on the treatment of end-stage renal disease.

    以腎臟照護為例,我們仍相信「推進美國腎臟健康」倡議將為患者帶來巨大的效益,並將居家透析作為第一線選項加以推廣。我們也持續培育此領域的創新產品管線,包括早期技術的進展,這些進展可能對末期腎臟病的治療帶來變革性的影響。

  • In Medication Delivery, we're building on our leadership in IV infusion systems and solutions with the internal innovation that is complemented by our expected acquisition of Cheetah Medical, the combination of which will fuel the broader impact of our integrated family of pumps, fluids, medications and monitors.

    在藥物輸注(Medication Delivery)方面,我們在靜脈輸注(IV)系統與解決方案的領導地位上持續深化,並以內部創新為基礎,且預期收購Cheetah Medical將形成互補;兩者結合將推動我們整合式產品家族(幫浦、輸液、藥物與監測設備)的更廣泛影響力。

  • In Pharmaceuticals, we're continuing to launch a steady stream of new molecules, including the recent introduction of Myxredlin, our new ready-to-use insulin for IV infusion.

    在製藥方面,我們持續推出一系列新分子,包括近期推出的Myxredlin——我們新的即用型靜脈輸注胰島素。

  • In sum, our business strategy objectives and capital allocation philosophy remains unchanged. We are focused on addressing unmet patient and customer needs, building our pipeline and successfully launching products across the globe. At the same time, we continue to actively pursue opportunities to extend our impact through strategic partnerships and business development initiatives. This all supports our goal to accelerate performance and deliver top-quartile results for all stakeholders.

    總而言之,我們的業務策略目標與資本配置理念維持不變。我們聚焦於滿足尚未被滿足的患者與客戶需求、建立產品管線,並在全球成功推出產品。同時,我們也持續積極尋求機會,透過策略夥伴關係與業務開發計畫擴大我們的影響力。這一切都支持我們加速績效、並為所有利害關係人交出同業前四分位的成果之目標。

  • Now we'll open the call up for Q&A, keeping in mind that we'll be limited in our ability to comment beyond the details we shared this morning.

    現在我們將開放問答,請記得我們在評論方面將受限於今天早上已分享的細節。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Catherine, you can open up the call for Q&A now.

    Catherine,現在可以開放問答了。

  • Operator

    Operator

  • (Operator Instructions) I would like to remind participants that the call is being recorded and a digital replay will be available on Baxter International website for 60 days at www.baxter.com. Our first question comes from David Lewis with Morgan Stanley.

    (接線員指示)提醒各位與會者,本次電話會議將被錄音,並將於百特國際網站提供為期60天的數位重播,網址為www.baxter.com。我們的第一個問題來自摩根士丹利(Morgan Stanley)的David Lewis。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • I want to get to fundamentals, guys. But just real quick, Joe, just in case we will be able to get this information, can you just give us any sense of how the issue was identified, any rough sense of when you hope to complete the investigation? And if not, I'll jump to some fundamental questions.

    各位,我想先談基本面。不過先很快問一下,Joe,萬一你們能提供這些資訊,你能否大致說明問題是如何被發現的,以及你們希望何時能完成調查的粗略時間點?如果不行,我就跳到一些基本面問題。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • David, as we said before, the investigation is in early stages. Beyond what we shared in our press release, I cannot provide additional information while the investigation is ongoing. So let's move to the business fundamentals.

    David,如同我們先前所說,調查仍在初期階段。除了我們在新聞稿中已分享的內容之外,在調查進行期間我無法提供更多資訊。所以我們來談業務基本面。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Okay. So look, given those FX dynamics, Joe, obviously, it's clouding the reporting structure, but obviously, underlying constant currency growth this quarter was solid. So just first question is, can you just give us a sense of underlying business trends this quarter, how you felt about those versus plan? As you think about underlying business performance into the end of the year, how do you feel about that sort of relative to plan? And any thoughts you can share about improving revenue performance in 2020? And then I got a quick follow-up for Jay.

    好的。那麼,Joe,考量那些外匯動態,顯然會讓報告架構變得更複雜,但本季以固定匯率計算的內生成長其實相當穩健。所以第一個問題是,你能否談談本季內在的業務趨勢,以及你們對照計畫的感受如何?當你們思考今年年底前的內在業務表現時,相對於計畫你們的感受如何?另外,對於2020年營收表現改善,你們有沒有任何想法可以分享?然後我有一個給Jay的簡短追問。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • So David, let me start with our Medication Delivery business. This is one that our investors have asked so many questions and paying a lot of attention. That business was able to perform very well. Actually, it slightly exceeded my expectations. And I will say that our new pump, our version 9 of our pump is doing very well, extremely well as a matter of fact. We finished our first full integration of that pump in the 2-way system, in a hospital system in the Southwest. We have closed many, many deals that I'm very excited about it. We also are seeing our -- a very stable business in our IV solutions, small- and large-volume parenterals with recovery now on its way and good contracts being signed, some of them surprisingly us being -- doing very well.

    所以,David,讓我先從我們的藥品輸送(Medication Delivery)業務談起。這是我們投資人問了非常多問題、也高度關注的一項業務。該業務表現非常好。事實上,略微超出我的預期。我也要說,我們的新幫浦——也就是第9代幫浦——表現非常好,實際上是極其出色。我們已在西南地區的一家醫院系統中,完成了該幫浦在雙向系統(2-way system)中的首次完整整合。我們已經簽下很多、很多筆交易,我對此非常興奮。我們也看到我們的IV輸液解決方案業務——小容量與大容量注射劑(parenterals)——目前呈現非常穩定的態勢,復甦正在進行中,且有不錯的合約正在簽署,其中有些甚至出乎我們意料——我們的表現非常好。

  • And this is a reflection on the performance of the U.S. Medication Delivery in the U.S. As I said, our head of that business, Heather, and her team in the U.S. are doing a wonderful job there. I want to highlight as well that our launch of PrisMax has been well received in the marketplace. It's one of the fastest launches I've seen. As soon as we launched it in the U.S., within a couple of days, we had purchase orders coming in. The system is really hitting the mark. And I feel the innovation of the company is really starting to bear fruit. So I'm excited about -- when we talk to you about 2020 about the impact of new product sales into next year.

    這反映了我們在美國的藥品輸送業務在美國的表現。如我所說,該業務在美國的負責人Heather以及她在美國的團隊做得非常出色。我也想強調,我們推出PrisMax在市場上獲得了良好回響。這是我見過最快的上市之一。我們在美國一推出後,短短幾天內就收到採購訂單。這套系統確實切中要點。我覺得公司的創新正開始開花結果。因此,當我們與各位談到2020年時,我對新產品銷售在明年帶來的影響感到興奮。

  • I also want to talk about the regions themselves. We see a full recovery in Europe. Europe was a real lagger for us and is coming out to be driving well our performance. And great performance in Asia Pacific as well led by China.

    我也想談談各個地區本身。我們看到歐洲已全面復甦。歐洲過去是我們相對落後的地區,現在正走出低迷,並成為推動我們業績的重要力量。亞太地區的表現也很出色,其中以中國為主導。

  • And I want to close by just saying the fundamentals of our PD business -- and this is one of the business when I first started here that we really were a bit concerned about because we had issues with contracts and we had issues with the ability to supply product. And seeing the product -- seeing the patient growth on a global basis is so high, in the U.S., nearly 10%, gives me tremendous confidence that when we hear back on the rule on AAKHI, that can really represent an opportunity for us.

    最後我想以我們PD業務的基本面作結——這是我剛加入時我們確實有點擔心的一項業務,因為我們在合約上有問題,也在供應產品的能力上有問題。而現在看到產品——看到全球範圍的病患成長如此之高,在美國接近10%,這讓我非常有信心:當我們收到關於AAKHI規則的回覆時,這確實可能為我們帶來機會。

  • So the fundamentals of the business puts me quite at ease in how we are doing in the marketplace, the share that we are expanding and our ability to really compete. This is a different Baxter.

    因此,該業務的基本面讓我對我們在市場上的表現、我們正在擴大的市占,以及我們真正競爭的能力感到相當安心。這是一個不一樣的Baxter。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Just 2 quick follow-ups. One is just I know it's challenging to talk about forward guidance just given the dynamics that are going on. But can you talk at all about -- you said building accelerated momentum in the business in 2019. How are you thinking about that momentum into 2020?

    再追問兩個很快的問題。第一個是,我知道在目前的動態之下,要談前瞻指引很具挑戰。但你能否談談——你提到2019年業務動能加速建立。你如何看待這股動能延續到2020年?

  • And then for Jay, margins always tick down in the fourth quarter. Can you just bridge us to fourth quarter any onetime benefits in the third, the headwinds into the fourth and how margin outlook is tracking relative to plan? And any comments you can make on pension, which is sort of an intraquarter announcement that we haven't yet got clarity on?

    第二個給Jay:毛利率在第四季通常都會下滑。你能否幫我們銜接到第四季:第三季是否有任何一次性利多、第四季有哪些逆風,以及相較於計畫,毛利率展望的追蹤情況如何?另外,對於退休金(pension)你能否評論一下?這算是季中宣布的事項,我們目前還沒有得到清楚的說明。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • So David, we don't have or I don't have any reason to think about any changes in dynamics that would slow down our ability to grow our businesses in the future. Why is that? Baxter has, for the most part of this, largest markets either driven by contracts, which are mid to long term, as well as large tenders outside the U.S. And we see a steady positioning of our products through contracts that give me comfort -- doesn't make me relax but gives me comfort that we're hitting the right places. The innovation coming through, our new pump platform coming on next year, gives me tremendous optimism in terms of how we're going to be able to face new opportunities in the U.S. We are also launching -- we launched the 3-chamber bag in Europe for Nutrition that is doing very well. Our post-Maria recovery in Nutrition, which was very slow in the beginning, we're starting to see some momentum. So I don't have any reasons today to tell you that I'm concerned about the ability of Baxter to grow its top line.

    所以,David,我們沒有——或者我沒有任何理由認為,會有任何動態變化使我們未來成長各項業務的能力放緩。為什麼這麼說?Baxter在其大多數最大的市場,主要是由中長期合約所驅動,此外在美國以外也有大型標案。我們看到透過合約讓產品穩定布局,這讓我感到安心——不代表我就放鬆,但讓我安心我們正在打到正確的點。創新正在推進,我們明年將推出的新幫浦平台,讓我對我們在美國面對新機會的能力非常樂觀。我們也正在推出——我們已在歐洲推出用於營養(Nutrition)的三腔袋(3-chamber bag),表現非常好。我們在Maria颶風後於營養業務的復甦,一開始非常緩慢,現在開始看到一些動能。因此,就目前而言,我沒有任何理由告訴你我擔心Baxter營收(top line)成長的能力。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Great. David, in relation to your question on margin versus expectation in sequential, I will tell you that Q3 was a very solid margin performance relative to our expectations. We were supported by top line in line with our expectations, which was great. But then as a result of savings initiatives and focus on efficiencies, we were able to come in maybe 1% ahead of our internal expectations.

    很好。David,針對你關於毛利率相較預期、以及環比變化的問題,我可以告訴你,第三季的毛利率表現相對於我們的預期非常扎實。我們的營收端符合預期,這很好。此外,由於節省成本的措施與效率提升的聚焦,我們的表現可能比內部預期高出約1%。

  • Now as we move from Q3 to Q4, you will note that the margin does deteriorate, which, as you pointed out, is largely attributable to normal seasonality. In the case of this fourth quarter, gross margin will come down. In large part, our shutdowns occur in Q4, and that has period expense impact in the fourth quarter. But then secondly, R&D in the third quarter, I believe, was a little bit below 5% of sales. We will expect it to go a little bit above 5% of sales in the fourth quarter related to the timing of certain milestone payments attributable to advancing the pipeline. So that's really the story on the overall margin evolution.

    接著從第三季走到第四季,你會注意到毛利率會惡化;如你所指出,這主要歸因於正常的季節性因素。在今年第四季的情況下,毛利率會下滑。很大一部分原因是我們的停工(shutdowns)發生在第四季,這會在第四季帶來期間費用的影響。其次,第三季的研發費用我認為略低於銷售額的5%。我們預期第四季會略高於銷售額的5%,這與推進研發管線所致的某些里程碑付款時點有關。這就是整體毛利率變化的主要原因。

  • As it relates to the pension, the overall goal of the pension approach is to really reduce volatility. As part of the transaction that we engaged in, we have reduced the liability by approximately $2.4 billion. That has very substantial long-term benefits to us in terms of managing the predictability of future financial results. But as it relates to commenting on the 2020 impact, in particular because this is an other income line item, I'll refrain from talking about whether this is a benefit or a headwind or tailwind. I'll stop my comments there and stick to the fact that this is more about a long-term reduction in volatility, which is why we pursued this transaction.

    至於退休金,整體退休金策略的目標是要真正降低波動性。作為我們所進行交易的一部分,我們已將負債降低約24億美元。這在長期上對我們管理未來財務結果的可預測性有非常顯著的好處。但就評論2020年的影響而言,特別是因為這屬於其他收入(other income)項目,我會避免談論這究竟是利多、逆風或順風。我的評論就到這裡,並強調這更多是關於長期降低波動性,這也是我們推動這筆交易的原因。

  • Operator

    Operator

  • Robbie Marcus from JPMorgan is on the line.

    JPMorgan的Robbie Marcus在線上。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • Joe or Jay, I was just hoping -- we didn't get constant currency by segment. We didn't get guidance by segment like you typically have. Any comments you could add to maybe where you're seeing pluses or minuses versus your internal plan or any deltas we should be expecting after third quarter results here?

    Joe或Jay,我只是希望——我們沒有拿到各事業部的固定匯率(constant currency)數據。我們也沒有像你們通常那樣提供各事業部的指引。你們能否補充一些評論,例如相較於你們的內部計畫,你們看到哪些地方有加分或扣分?或者在第三季結果之後,我們應該預期有哪些差異(deltas)?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Sure. Robbie, just for -- as a matter of clarification, the reason that we have not provided sales growth by segment or by region is that as part of any correction to previously issued financial statements, after we complete this investigation, we do expect to correct certain items that are immaterial to our previously reported results of operations, which include the impact of translating our foreign operations back to U.S. dollars in the exchange rate used. Like I said, this is an immaterial impact, but you can imagine how sensitive we are to any minor changes in growth rates that may emerge as a result of comparisons in this kind of situation. So I think Joe -- so that's why, for your information, we haven't shared anything in relation to growth by segment, by region.

    當然可以。Robbie,先澄清一下:我們之所以沒有按事業部或地區提供銷售成長,是因為作為對先前已發布財務報表的任何更正的一部分,在我們完成這項調查後,我們預期會更正某些對先前已報告營運結果並不重大(immaterial)的項目,其中包括將海外營運換算回美元時所使用匯率的影響。如我所說,這影響並不重大,但你可以想像,在這種情況下,任何因比較而可能出現的成長率微小變動,我們都會非常敏感。所以我想Joe——因此,供你參考,這就是我們沒有分享按事業部、按地區成長相關資訊的原因。

  • But I think Joe said it well. Look, we had strength across the portfolio. Our Renal Care business continues with great momentum. Medication Delivery had a very solid performance in particular in the U.S. as we look to continue to drive performance in that area. The Pharmaceuticals business, not only did we couple solid performance in the quarter, but we added to that the launch of Myxredlin, which becomes an important driver for our long-term growth. So I would say, generally speaking, we sit here very pleased with the business momentum across the board.

    但我認為 Joe 說得很好。你看,我們的整體產品組合表現強勁。我們的腎臟照護業務持續展現強勁動能。藥物輸注業務表現非常穩健,特別是在美國;我們也希望持續推動該領域的表現。製藥業務不僅在本季繳出穩健表現,我們也推出了 Myxredlin,這將成為我們長期成長的重要驅動力。所以我會說,整體而言,我們對各項業務全面性的動能感到非常滿意。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • I echo Jay. And I tell you, I just want to point to really the acceleration of PD business. The patient growth has been impressive and not surprising because the therapy is a desirable therapy for the home. But this is one of the levers that we have. And the other lever that we have is also the momentum in our U.S. Medication Delivery business, which we're starting to see the fruits of our change in sales force structure and organization.

    我同意 Jay 的看法。我想特別指出的是 PD 業務的加速成長。病患成長令人印象深刻,而且並不意外,因為這種療法非常適合居家使用、也很受青睞。但這是我們可以運用的其中一個槓桿。另一個槓桿則是我們美國藥物輸注業務的動能;我們開始看到銷售團隊架構與組織調整所帶來的成果。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • Great. And then quick clarification, Jay. Might there possibly be cash flow restatements? Or is this purely just a P&L item?

    很好。接著快速釐清一下,Jay。是否有可能需要重編現金流量?還是這純粹只是損益表(P&L)項目?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • So at this point, Robbie, we can't comment on any -- we're limiting our comments today to operating income. We have an investigation ongoing. Upon the conclusion of that, we'll be prepared to share further comments. But for purposes of our discussion here, we're not commenting on anything below operating income.

    Robbie,就目前而言,我們無法評論任何——我們今天的評論範圍僅限於營業利益。我們正在進行調查。待調查結束後,我們會準備好分享進一步的說明。但就我們在此的討論而言,我們不評論任何低於營業利益的項目。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • Okay. And then just last quickly for me. Jay, we saw some recent news reports that you might be in discussion with a pharma company for a specific drug. Can you just give us your latest thoughts on the use of capital specifically for M&A and what type of deals you're looking for that might be most appropriate for Baxter here?

    好的。最後再快速問一個。Jay,我們看到近期有新聞報導指出,你們可能正與某家製藥公司就某一特定藥品進行討論。你能否談談你們對資本運用的最新想法,特別是在併購(M&A)方面,以及你們認為對 Baxter 最合適的交易類型是什麼?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Robbie, this is Joe. Great question. We don't comment on any M&A activity that we are contemplating or not. But I think you have a great question when it comes about capital allocation. Capital allocation, as we've mentioned, remains unchanged. We are -- we always prefer strategic deployment of capital into acquisitions. We said before that adjacencies are more reasonably priced and easier to integrate, and we are very open to those. We also have not changed our view on dividends at all and how -- at the end of the day, we're not going to be hoarding cash. So if we find ourselves with excess cash in our balance sheet, we make a decision to appropriately buy shares back. So I just want to say to you and to the folks on the call that no change has been contemplated neither in sight to our current capital allocation policy.

    Robbie,我是 Joe。問得很好。我們不評論任何我們正在考慮或未在考慮的併購活動。但你在資本配置方面的問題非常好。如同我們提過的,資本配置政策維持不變。我們——我們一向偏好將資本策略性地投入於收購。我們之前也說過,相鄰領域(adjacencies)的估值通常更合理、也更容易整合,我們對此非常開放。我們對股利的看法也完全沒有改變;歸根結底,我們不會囤積現金。因此,如果我們在資產負債表上出現多餘現金,我們會做出適當的決策來回購股票。所以我想對你以及電話會議上的各位說明:我們目前的資本配置政策沒有考慮任何改變,眼前也沒有改變的跡象。

  • Jay, anything on that?

    Jay,對此還有補充嗎?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • No, that's a great summary. The only thing to add is -- and Robbie, of course, we have very ample liquidity with significant cash on hand to fund business development or any other activities we are interested in pursuing.

    沒有,這個總結很好。唯一要補充的是——Robbie,當然,我們的流動性非常充裕,手上有相當可觀的現金,可用於資本開發(business development)或任何其他我們有興趣推動的活動。

  • Operator

    Operator

  • And Bob Hopkins of Bank of America is on the line.

    美國銀行的 Bob Hopkins 在線上。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • First question is I just wanted to clarify something in your 8-K and make sure I'm reading it correctly. Because it says the FX gains for '14 to '18, you list those out. Should we view those as representing the magnitude of the misstatement? Or could those misstatements be, I guess, in the end larger or smaller?

    第一個問題是,我想釐清你們 8-K 裡的一點,確認我是否解讀正確。因為上面列出了 2014 到 2018 年的外匯(FX)收益。我們是否應將那些數字視為錯誤陳述的幅度?或者最終這些錯誤陳述可能更大或更小?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • The misstatements could be larger or smaller than what was reported as gains on -- in the 8-K that we issued.

    錯誤陳述的金額可能會大於或小於我們在所發布的 8-K 中所報告的收益。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • Okay. And just the -- one of the other things in the 8-K was on Claris. It sounds like the FDA process is going a little slower. Jay, can the contingency plans that you guys have talked about prevent the potential for disruption there? Or just how should we be thinking about that?

    好的。另外,8-K 裡還有一點是關於 Claris。聽起來 FDA 的流程進度有點慢。Jay,你們先前提到的應變計畫能否避免那邊可能出現的供應中斷?或我們應該如何看待這件事?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Bob, we are just being cautious. We can't predict when the FDA will come in and reinspect the plant. We have not been reinspected yet, and we're coming towards the end of 2019. We have done everything that we committed to do to date for the FDA. We have improved our operations. We have modified facilities. We have done a lot of different things that we -- as we promised. But we can't predict, so we're better off just not counting on something. And if it comes, fine. If it doesn't, at least we're upfront telling you.

    Bob,我們只是採取較為審慎的態度。我們無法預測 FDA 何時會來進行工廠的複查。我們尚未接受複查,而現在也接近 2019 年底。截至目前,我們已完成所有對 FDA 承諾要做的事項。我們改善了營運。我們改造了設施。我們做了許多不同的事情——如同我們承諾的那樣。但我們無法預測,因此我們最好不要把某件事當作必然會發生。如果發生了,那很好。如果沒有,至少我們坦白先告訴你。

  • But what you need to think about is that we are committed for a backup plan, and we're investing money to have most of these products on a CRO basis if we ever need to activate CROs. So our pharmaceutical group not only is very busy right now with significant amount of new opportunity in pipeline they will be formulating -- the example is Myxredlin, but they also will be working on continuing closing all these CRO opportunities for -- as a backup.

    但你需要了解的是,我們承諾會有備援方案,而且我們正在投入資金,讓這些產品多數能以委外方式進行;若有需要,我們可以啟動委外合作夥伴。因此,我們的製藥團隊目前不僅因為管線中大量新機會而非常忙碌、他們會進行配方開發——例如 Myxredlin;同時他們也會持續推進並完成這些委外機會的洽談,作為備援。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • Okay. Sounds like the potential for disruption is low there.

    好的。聽起來那邊發生中斷的可能性不高。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Oh, I just want to rephrase. I incorrectly used the contract manufacture organization, and I used CRO, which is contract research organization. I apologize to distract that from the -- CMO, CMO organizations. I'm very sorry.

    噢,我想重新表述一下。我剛才把「委外製造組織」說錯了,我用了 CRO(委外研究機構,contract research organization)。抱歉造成混淆——應該是 CMO,委外製造組織(contract manufacturing organization),CMO 機構。非常抱歉。

  • Operator

    Operator

  • And Matt Taylor with UBS is on the line.

    UBS 的 Matt Taylor 在線上。

  • Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices

    Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices

  • So I was hoping you could comment on the PV dynamics. And do you think you're seeing a pickup in the patient volumes because of technology, because of the initiatives that the government has talked about or some combination thereof?

    我希望你們能評論一下 PV 的動態。你們認為病患量的提升是因為技術、因為政府所談到的倡議,或是兩者的綜合作用?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Well, I think that the therapy's benefit was always very clear, but I think that our -- there is an acceptance of the therapy probably more widely today than was before. But I have to say that our partners, DaVita being one of them, have been working very closely with us in a very collaborative manner. And that has created the opportunity for us to continue to deploy our resources to train nurses and patients.

    我認為這項療法的效益一直都很明確,但我覺得如今對這項療法的接受度,可能比以前更為普遍。但我必須說,我們的合作夥伴——DaVita 是其中之一——一直以非常協作的方式與我們密切合作。這也讓我們有機會持續投入資源,訓練護理人員與病患。

  • I also underscore that Baxter has made significant operational changes in making products, what we make, how much capacity we're putting in place, giving confidence to our partners that we can actually supply the market versus perhaps back in 2013, '14 and '15 when we had some constraints in allocation of resources. So if now the clinics and their doctors and our partners feel more confident, I think that plays a role, but I also think the move into the home is becoming more perfectly apparent to our constituents. This is a good result, and we'll be working very hard to make sure that we continue on with these partnerships.

    我也要強調,Baxter 在製造營運方面做了重大調整:我們生產什麼、如何生產、以及我們正在建置多少產能,這些都讓合作夥伴更有信心,相信我們確實能供應市場;相較之下,在 2013、2014 與 2015 年,我們在資源配置上曾有一些限制。因此,如果現在診所、他們的醫師以及我們的合作夥伴更有信心,我認為這確實扮演了一定角色;但我也認為,走向居家治療的趨勢,對我們的利害關係人而言正變得更加明顯。這是個很好的成果,我們也會非常努力,確保能持續推進這些合作關係。

  • Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices

    Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices

  • And then just to follow up on Med Del, so the U.S. number was very strong, but the OUS was a little below what the consensus was expecting. Can you talk a little bit about the dynamics OUS, if that growth could improve? And then when do you think we'll start to see more inflection from the new pump launches?

    接著追問一下 Med Del,美國的數字非常強勁,但美國以外(OUS)略低於市場共識預期。你能否談談 OUS 的一些動態,以及那邊的成長是否有機會改善?另外,你認為我們何時會開始從新幫浦產品上市看到更明顯的拐點?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • So I think there was some timing on the performance outside the U.S. Also, we have focused tremendously in making sure that we have launched our new pump, Evo IQ, what's outside the U.S. We had a slow launch of that product in the U.K., which is going to be picking up momentum later this year into next year. That was a little bit of the weakness that we found there as well. And -- but we had a very good momentum in Latin America, very good momentum, and we are on track on that. And then we also -- in Canada, we just launched our new pump there.

    我認為美國以外的表現有一些時點因素。另外,我們也非常專注於確保在美國以外推出我們的新幫浦 Evo IQ。我們在英國對該產品的上市節奏較慢,預計今年稍晚到明年會逐步加速、帶動動能。這也是我們在那裡看到些許疲弱的原因之一。不過,我們在拉丁美洲的動能非常好、非常強,而且我們在那方面進展如期。此外,我們也——在加拿大剛推出了我們的新幫浦。

  • So don't read anything on the OUS numbers. More so, you should feel comfortable that in the U.S., we got this thing addressed, and we've got the numbers right. And we don't talk about comparison at the moment. We're not going to be talking about quarter-over-quarter or year-over-year. But I can tell you that based on my expectations, this business is doing well. It's doing well, and I'm very happy with the performance that we have demonstrated that at one point in time was being quite challenged by other constituents. We are on track on that.

    所以不要對 OUS 的數字做過度解讀。更重要的是,你們應該可以放心:在美國,我們已把這件事處理到位,數字也已經校正正確。我們目前不談比較。我們不會談季對季或年對年的比較。但我可以告訴你,依照我的預期,這個業務表現得很好。它表現得很好,我也對我們所展現的績效非常滿意——在某個時間點,這項業務曾被其他利害關係人認為面臨相當大的挑戰。我們在這方面進展如期。

  • Operator

    Operator

  • And our next question is Pito Chickering with Deutsche Bank.

    下一個問題來自德意志銀行(Deutsche Bank)的 Pito Chickering。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Two quickies for me. What is the process for getting THERANOVA approved for the Medicare transitional add-on payment in 2020?

    我有兩個很快的問題。在 2020 年,讓 THERANOVA 取得 Medicare 過渡性附加給付(transitional add-on payment)核准的流程是什麼?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Well, I don't want to get into the sausage making because there's a lot of work being done. We have a full team. But we are -- we submit our comments to HHS, and we also have submitted our THERANOVA for the de novo process. So I'm very happy. Our team, led by Laura Angelini and Tony Woodson, have done a great job in getting this on time to the FDA. Now is the comments need to go in, and they need to come back with the final resolution about the process itself. Remember, it does not only affect our product but affects other categories of medical devices. But we are -- we're confident. We're seeing some of the early data that was done outside the U.S. on THERANOVA, and we find that to be very compelling. I think the HHS saw that as well.

    我不想把整個「製作香腸」的過程講得太細,因為目前有很多工作正在進行。我們有一個完整的團隊。但我們已向 HHS 提交意見,也已將 THERANOVA 送交 de novo 流程。所以我非常高興。我們的團隊在 Laura Angelini 和 Tony Woodson 的帶領下,準時把資料送到 FDA,做得非常好。接下來是意見需要提交,然後他們需要就流程本身給出最終結論。請記得,這不只影響我們的產品,也會影響其他醫療器材類別。但我們——我們有信心。我們看到一些在美國以外針對 THERANOVA 所做的早期數據,覺得非常有說服力。我認為 HHS 也看到了這一點。

  • So we're on track. But remember, this is not a 2020 conversation. This is a 2021 conversation, okay, because this is going to take us time. By the time we get to the product approved and get this -- the reimbursement firmed, we'll take about 12 months to start implementing.

    所以我們進展如期。但請記得,這不是 2020 年的議題。這是 2021 年的議題,好嗎?因為這需要時間。等到產品獲批、並把給付(reimbursement)確定下來後,我們大約還需要 12 個月才會開始落地實施。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Perfect. So assuming that, that isn't accepted for the add-on payment, the providers will start getting paid for -- with that add-on payment in 2021, correct?

    了解。所以假設它被接受納入附加給付,服務提供者將在 2021 年開始收到包含該附加給付的款項,對嗎?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • That is correct. This is our best estimate right now. If anything changes, we'll let you guys know in one of our calls.

    沒錯。這是我們目前最好的估計。如果有任何變化,我們會在之後的電話會議中告訴各位。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Okay. And then from a manufacturing capacity of the dialyzers, it sounds like there are some capacity constraints this quarter. Can you talk about what investments you're making in those facilities and how fast you think those facilities can get ramped up?

    好的。另外,關於透析器(dialyzers)的製造產能,聽起來本季有一些產能限制。你能談談你們在這些設施上正在做哪些投資,以及你認為這些設施能以多快的速度擴產爬坡嗎?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Well, listen, we -- at one point in time, a few years ago, I would say, about 3 years ago, we had 2 lines within our plant in Alabama that were not operational. We did not enable them to start operating because the capacity versus demand was balanced. As we start getting more successful in the dialyzer business and start selling more product, we activate those lines. Those are complex lines, and we had issues in getting them started up. So we will have some investments that we're making in quality and operations in this plant for the next 12 months. We're going to increase our -- the amount of investment in that plant to make sure that the lines will be ready to be converted to THERANOVA if we decide to do so. But we need to do some investment, some expenses that will go up a little bit next year in terms of enabling that plant to be fully capable of making THERANOVA or Revaclear. And then we're going to decide which is the best mix for our patients and for our customers and also for Baxter in general.

    好,聽我說——我們在幾年前,我會說大約 3 年前,我們阿拉巴馬州工廠裡有 2 條產線是沒有運作的。我們當時沒有讓它們啟動,因為產能與需求是平衡的。隨著我們在透析器業務上越來越成功、產品銷量增加,我們就啟動那些產線。那些是複雜的產線,我們在啟動過程中遇到一些問題。因此,接下來 12 個月我們會在該工廠的品質與營運方面進行一些投資。我們會提高——對該工廠的投資金額,以確保這些產線在我們決定要這麼做時,能夠準備好轉換生產 THERANOVA。但我們需要做一些投資,明年在費用面會略有上升,以使該工廠具備完整能力來生產 THERANOVA 或 Revaclear。接著我們會決定哪一種組合對病患、對客戶、以及對 Baxter 整體而言是最佳的。

  • Operator

    Operator

  • We have Larry Keusch with Raymond James on the line.

    線上有 Raymond James 的 Larry Keusch。

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Joe, I just wanted to maybe talk a moment about the

    Joe,我想也許花一點時間談談這個

  • (technical difficulty)

    (技術問題)

  • delivery business. Obviously, you did the Cheetah Medical deal, which is interesting. But as we get past this year and you kind of stabilize the business, what's really the right way to think about the growth outlook and what you'll be focused on over the next several years?

    給藥輸注(delivery)業務。顯然你們做了 Cheetah Medical 的交易,這很有意思。但當我們度過今年、你們把業務穩定下來之後,接下來幾年應該如何看待成長前景?你們未來幾年會把重點放在哪裡?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Well, I had a great discussion with the head of that business, David Ferguson, the other day. And for us, the vision of that business is preventable harm. How do we create a system that integrate pumps and fluids that you continue to treat the most critical patients in a way that they can recover and exit the critical stage faster either in the septic stage or any acute other stage?

    我前幾天和該業務負責人 David Ferguson 做了一次很好的討論。對我們而言,這個業務的願景是「可預防的傷害」(preventable harm)。我們如何建立一個整合幫浦與輸液的系統,讓你能以一種方式持續治療最危重的病患,使他們無論是在敗血症階段或任何其他急性階段,都能更快恢復並更快脫離危急期?

  • So we find that the hemodynamic balance of the patient to be very important to us. So we start with PIVA, which we started our clinical trials actually a couple weeks ago. Then Cheetah comes in and give us more qualitative data in terms of the treatment of that patient. But there are other things that we're looking around, a series of monitoring technologies that will come to surround our patient in the ICU to be able to get that patient out of the critical condition as fast as possible. And to that, we can also think about -- don't think about Medication Delivery exclusively. Think about our acute renal care therapy, our CRRT therapy because that plays a role also, not only feeding but also helping diagnose and determine when to start. Because the patient, when it gets to the point that you're checking the hemodynamic balance, you're checking the quality of that treatment, is also a patient that sometimes has acute kidney injury and is incapable of doing -- the kidneys are not operating anymore. So all of this together, how do we create a business for critical care patients that prevents harm and improves the ability of that patient to get out of the critical stage?

    因此,我們認為病患的血流動力學平衡(hemodynamic balance)對我們非常重要。所以我們從 PIVA 開始;我們其實在幾週前就啟動了臨床試驗。接著 Cheetah 進來,為我們提供更多關於該病患治療的定性資料。但我們也在評估其他事項——一系列監測技術,將在加護病房(ICU)中圍繞病患,讓我們能盡可能快地讓病患脫離危急狀態。此外,我們也可以這樣思考——不要只把它當作「給藥輸注」(Medication Delivery)。也要把我們的急性腎臟照護治療、我們的 CRRT 治療納入思考,因為它也扮演角色:不只是支持治療,也有助於診斷並判斷何時開始介入。因為當病患到了你在檢查血流動力學平衡、檢查治療品質的那個階段時,這樣的病患有時也會出現急性腎損傷,腎臟已無法運作。所以把這一切整合起來,我們如何為重症照護病患打造一個能預防傷害、並提升病患脫離危急期能力的業務?

  • So you're going to see a lot of different movements from Baxter in this area that was not, in the past, a priority for us because we think having the best pump platform that is coming out next year is one lever. Having the fluids available for the hospital is a second lever. But now how do you create this net, this safety net that can bring the patient to a better outcome faster?

    因此,你將會看到 Baxter 在這個領域有許多不同的動作;過去這並不是我們的優先事項,因為我們認為,明年推出的最佳幫浦平台是一個槓桿。為醫院提供可用的輸液產品是第二個槓桿。但現在要如何建立這張網、這個安全網,讓病人更快獲得更好的治療結果?

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Okay. So just a quick follow-up on that one question. So it sounds like the aspirations are clearly to grow this business in totality sort of faster than the low single-digit growth of the markets. Is that fair?

    好的。那就針對那個問題做個簡短追問。聽起來,你們的目標很明確,是要讓這項業務的整體成長速度快於市場的低個位數成長。這樣理解對嗎?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • That is fair. That is fair. Remember, we have a very large and stable business within Medication Delivery which are fluids. And for that, we're working very hard and have worked very hard to stabilize, get the contracts in place, get the supply chain in place. So this was Phase I because without that, it's a nonstarter. So we start doing that, and that became our priority. Now the second priority, so let's get a pump platform that has all the pumps that they need. And they are connected. They are 2-way communications. And how do we make them more intelligent? Third, how do you surround that patient with a safety net that promotes -- that prevents harm and allows the patient to get out of critical care faster?

    沒錯。沒錯。請記得,我們在藥物輸送(Medication Delivery)中有一個非常龐大且穩定的業務,也就是輸液產品。針對這部分,我們一直非常努力、也已經非常努力地去穩定它,把合約到位、把供應鏈到位。所以這是第一階段,因為沒有這些,一切都無從談起。因此我們先做這些,這也成為我們的優先事項。現在第二個優先事項是:打造一個幫浦平台,涵蓋他們所需要的所有幫浦。而且它們是互聯的。它們具備雙向通訊。我們要如何讓它們更智慧?第三,如何用一個安全網把病人包圍起來,促進——防止傷害,並讓病人更快離開重症照護?

  • So you see this all comes together, but we had to do it in phases because we had a business that was a little bit in disarray. And now we have that business that's quite organized, quite ready to go. And by the way, when we look at the people selling this, the whole restructuring of the sales force that we're putting in place not only in the U.S. but other parts of the world, is because we're going to have a global pump product. This is not about the U.S. anymore. That makes it, I'd say, the fourth pillar of having this business completely revamped.

    所以你會看到這一切是如何整合在一起的,但我們必須分階段進行,因為我們原本的業務有點混亂。而現在我們已經把那項業務整理得相當有條理、也相當準備就緒。順帶一提,當我們看銷售這些產品的人員時,我們正在推動的整個銷售團隊重整,不僅在美國,也在世界其他地區,原因是我們將會有一個全球性的幫浦產品。這不再只是美國的事。我會說,這讓「讓這項業務徹底翻新」成為第四個支柱。

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Okay. Perfect. And then just quickly, Jay, just while you're moving through the investigation here on the accounting misstatements, I just want to confirm whether you can deploy capital during that period. Meaning, are you free to do M&A? And more specifically, are you free to buy back stock?

    好的。很好。接著很快問一下,Jay,當你們在推進這次針對會計錯誤陳述的調查時,我想確認你們在那段期間是否仍能進行資本配置。也就是說,你們是否可以自由進行併購(M&A)?更具體地說,你們是否可以自由回購股票?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • So just to be clear, obviously, we commented on this a number of times. The organization here takes the matter incredibly seriously. The management team, Audit Committee of the Board, there is an ongoing investigation, and we intend to move through it expeditiously.

    先說清楚,顯然我們已經就此多次發表評論。本組織對此事極為重視。管理團隊、董事會審計委員會目前都有一項正在進行的調查,我們打算以最快速度推進並完成。

  • As far as capital deployment, our -- on the M&A side, our principles have not changed, and we have ample cash to deploy. And so that's what I would say. In terms of our current deployment of capital, that would be the priority focus.

    就資本配置而言——在併購(M&A)方面,我們的原則沒有改變,而且我們有充足的現金可以運用。所以我會這麼說。至於我們目前的資本配置,這將是優先聚焦的重點。

  • Operator

    Operator

  • Danielle Antalffy with SVB Leerink is on the line.

    SVB Leerink 的 Danielle Antalffy 在線上。

  • Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst

    Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst

  • Jay -- Joe and Jay, I know you're not going to provide 2020 guidance. I'm not asking you to, but just for -- at a high level, as I look out to 2020, it feels like you have a lot of tailwinds in place, new product launches that you had here in 2019 across most of the businesses. And I know some of the headwinds, I appreciate some of those back half Med Delivery comps will get tougher. You also had in the acute surgery business that supply disruption from a competitor. Just at a high level, can you help frame for us the tailwinds and headwinds from a top line perspective as we head into 2020, especially as you're exiting the year here at what seems like it would be a 5% organic growth rate?

    Jay——Joe 和 Jay,我知道你們不會提供 2020 年的指引。我不是要你們提供,但就——從高層次來看,當我展望 2020 年時,感覺你們有很多順風因素到位:2019 年你們在大多數業務都有新產品上市。我也知道有些逆風因素;我理解藥物輸送(Med Delivery)下半年的一些比較基期會變得更具挑戰。另外在急性手術業務方面,你們也受惠於競爭對手的供應中斷。就高層次而言,能否從營收角度幫我們框架一下,進入 2020 年時有哪些順風與逆風,特別是你們在今年結束時看起來有約 5% 的有機成長率?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Thanks for the question, Danielle. I think overall, what I will say is we're pleased with the momentum and the progress that we're seeing, as I said earlier, really across the portfolio. The third quarter from a sales perspective hit on a lot of different cylinders. And furthermore, as we looked at the performance of the pipeline in innovation and new products, that -- those were all pointing in the right direction.

    謝謝你的問題,Danielle。我想整體而言,我要說的是,我們對目前看到的動能與進展感到滿意,正如我先前所說,確實是橫跨整個產品組合。第三季從銷售角度來看,多個面向都有所發揮。此外,當我們看創新與新產品的研發管線表現時——那些也都朝著正確方向前進。

  • As far as 2020 goes, as we always do this time of year, we really do hold off on specific guidance for 2020 and specific headwinds and tailwinds. And the reason is we are literally in the process of completing our annual operating plan. In the coming weeks and months, we'll review it with our Board of Directors and walk them through it as we prepare for the new year, at which point we'll share guidance.

    至於 2020 年,如同我們每年這個時候一貫的做法,我們確實會先不提供 2020 年的具體指引,以及具體的順風與逆風因素。原因是我們正處於完成年度營運計畫的過程中。在接下來幾週到幾個月,我們會與董事會審閱並逐一說明,為新年度做準備,屆時我們會分享指引。

  • And then as we think about this year in particular, there are a number of different items that are -- that could have an interesting impact on our financials, things like the Advancing American Kidney Health initiative, which is an important potential driver for us. We also have to ensure that we have the right capital investments and operational investments in our manufacturing and quality systems. That's another critical area we are spending a lot of time assessing that. And then finally, one of the key areas to our long-term success relates to agreements with GPOs, IDNs and other major customers. And so that's another area that we are working -- our U.S. teams are working very hard on that.

    另外,當我們思考今年特別的情況時,有若干不同事項——可能會對我們的財務產生有趣的影響,例如「推進美國腎臟健康(Advancing American Kidney Health)」倡議,這對我們而言是一個重要的潛在驅動因素。我們也必須確保在製造與品質系統上有正確的資本投資與營運投資。這是另一個關鍵領域,我們正在投入大量時間進行評估。最後,與我們長期成功相關的一個關鍵領域,是與 GPO、IDN 及其他主要客戶的協議。因此這也是我們正在推進的領域——我們的美國團隊正非常努力地處理。

  • And so until we have full line of sight to the completed operating plan along with some further information on these numerous critical drivers, it's a little too early to get into specifics on 2020.

    因此,在我們對已完成的營運計畫有完整能見度,並且對這些眾多關鍵驅動因素取得更多資訊之前,現在談 2020 年的細節還稍嫌太早。

  • Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst

    Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst

  • No, that's helpful. And just one quick follow-up. As it relates to capital deployment, we touched on your ability to do M&A while this investigation is ongoing. What about your ability to continue to buy back shares? Can you do that before you file the 10-Q? Or are you limited on what you can do there?

    不,這很有幫助。再快速追問一個。關於資本配置,我們剛剛談到在調查仍在進行期間,你們進行併購(M&A)的能力。那你們持續回購股份的能力呢?在你們提交 10-Q 之前可以做嗎?或者你們在這方面會受到限制?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • We don't -- so generally speaking, we don't comment on share repurchases for a lot of different reasons. What we typically do is after having repurchased shares, we make comments on how many shares we repurchased. And there are a number of different reasons for that, that I think represent good practice. And so as it relates to going forward, stay tuned, we'll talk about share repurchases on an upcoming call.

    我們不——一般而言,基於許多不同原因,我們通常不評論股票回購。我們通常的做法是在回購股份之後,才會說明我們回購了多少股份。這麼做有許多不同原因,我認為這代表良好的做法。因此,至於未來的安排,敬請期待,我們會在接下來的電話會議中談到股票回購。

  • Operator

    Operator

  • Vijay Kumar with Evercore ISI is on the line.

    Evercore ISI 的 Vijay Kumar 在線上。

  • Vijay Muniyappa Kumar - MD

    Vijay Muniyappa Kumar - MD

  • Hello?

    哈囉?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes, Vijay. Vijay, we can hear you.

    是的,Vijay。Vijay,我們聽得到你。

  • Vijay Muniyappa Kumar - MD

    Vijay Muniyappa Kumar - MD

  • Sorry about that. Can you hear me now?

    抱歉剛剛那樣。你們現在聽得到我嗎?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes, we can. We're good.

    是的,我們聽得到。沒問題。

  • Vijay Muniyappa Kumar - MD

    Vijay Muniyappa Kumar - MD

  • So one, maybe on the fundamental side, Joe, Jay. On the 5% operational for Q4, it looks like -- sequentially, what changed? What changes, I guess, in the model? Because you do have a tougher comp Q4. I'm guessing some of this is on the pharma side. The BREVIBLOC headwind goes away. You spoke about Myxredlin. Are those the main drivers here just to offset the tougher comp?

    所以第一個,可能從基本面來看,Joe、Jay。關於第四季 5% 的營運表現,看起來——按季來看,變了什麼?我想問的是,模型裡有哪些變化?因為你們第四季的比較基期更具挑戰。我猜其中一些是在製藥端。BREVIBLOC 的逆風消失了。你們也提到 Myxredlin。這些是否就是主要驅動因素,用來抵消更艱難的比較基期?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. I mean as we always anticipated, there was an acceleration in Q4 in Medication Delivery that represents an important driver. The team is hard at work in terms of identifying new customers, doing a tremendous job on the pump side and also the large-volume solutions side. So that Medication Delivery does represent an important component as we look to close out the year successfully. And then we'll also see some improvement sequentially in Nutrition. Again, that's an important business for us. The team has been hard at work recapturing some of the lost business in the U.S. but along with also successfully launching products. So those will be a couple of things that I would point out. I don't know, Joe, if you would add anything to that?

    是的。我的意思是,如同我們一直預期的,第四季在藥物輸注(Medication Delivery)方面出現加速,這是重要的驅動因素。團隊正努力辨識新客戶,在幫浦端以及大容量輸液端都做得非常出色。因此,藥物輸注確實是我們在成功收官今年時的重要組成。另外,我們也會看到營養(Nutrition)業務按季有所改善。同樣地,這對我們是重要的業務。團隊一直努力在美國市場收復部分流失的業務,同時也成功推出產品。所以這是我會指出的幾個重點。我不知道,Joe,你是否要補充?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • I would say, Vijay, that compounding has had an effect. On a sequential basis, we have -- we've been very successful with compounding. But compounding is a business that varies a lot based on what kind of drugs go into biosimilars and mineral compounding business outside the U.S. So biosimilars are very successful outside the U.S., so depends on when they go on. On biosimilars, we have not a reduction in profit, but we have a reduction in the -- in sales just because of the purchase price.

    我會說,Vijay,代工調配(compounding)確實有影響。就按季而言,我們——我們在代工調配方面非常成功。但代工調配是一個波動很大的業務,取決於哪些藥品進入生物相似藥(biosimilars)以及美國以外的礦物調配業務。所以生物相似藥在美國以外非常成功,因此也取決於它們何時上線。在生物相似藥方面,我們不是利潤下降,而是銷售額下降,原因只是採購價格。

  • The other one is we're anniversarying dexmed. Remember, this is a $80-plus million business that we're anniversarying right now. Myxredlin is just starting to pick up the momentum. We're picking up -- starting to see sales go up on that insulin -- ready-to-use insulin product. But the Myxredlin -- I'm sorry, but the dexmed anniversaries in there. So there are some puts and takes in the whole quarter, but it's not -- no, I don't see anything terribly different that would alter the momentum.

    另外一個是我們正在進入 dexmed 的周年比較。記得,這是一個超過 8,000 萬美元的業務,我們現在正在做周年比較。Myxredlin 才剛開始累積動能。我們開始看到那個胰島素——即用型胰島素產品的銷售上升。但 Myxredlin——抱歉,是 dexmed 的周年因素在裡面。所以整個季度有一些此消彼長,但——不,我沒有看到任何非常不同、會改變動能的事情。

  • Vijay Muniyappa Kumar - MD

    Vijay Muniyappa Kumar - MD

  • And Jay, just on the 2020 commentary that you made on -- I think if you heard you correctly, you were talking about CapEx investments. So I just want to put that into context. Just given free cash has been growing healthily, are we looking at a step-up in CapEx? Was that the genesis of the comment or not? And just on the topic of free cash, when you look at deploying the free cash between now and until the investigation gets resolved, can you buy back stock, right, I guess, is -- and I apologize if this has been asked. But with that, I'll stop. Hello?

    Jay,另外關於你對 2020 的評論——我想如果我沒聽錯,你是在談資本支出(CapEx)投資。所以我想把它放在脈絡裡。考量自由現金流一直健康成長,我們是否會看到 CapEx 的提升?那是否是你那段評論的出發點?另外就自由現金流的運用而言,在調查結案之前,你們在配置自由現金流時,是否可以回購股票?我想——也抱歉如果這題有人問過。那我就先到這裡。哈囉?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • So yes -- sorry, Vijay. A couple of things. As it relates to your question on capital, my comments about 2020, I highlighted a few drivers. The AAKHI, that initiative is an important long-term growth driver for us. We have not reflected that particular initiative in our long-term plans but also in terms of our short-term capital plans. So that would be above and beyond our prior expectations in terms of CapEx investment.

    所以是的——抱歉,Vijay。有幾點。就你關於資本的問題而言,我在談 2020 時強調了幾個驅動因素。AAKHI,那個計畫是我們重要的長期成長驅動。我們過去並未把這個特定計畫反映在長期規劃中,也沒有反映在短期資本規劃中。因此,就 CapEx 投資而言,這會高於我們先前的預期。

  • As it relates to manufacturing and quality, one of the things we are intensely focused on is ensuring the high-quality manufacturing and that we have the right investments in quality. And that comes in 2 forms: OpEx certainly and also some CapEx. So that's another feature that we're looking at as we think about our 2020 planning. So those are a couple of highlights. And I've just chosen a few things to highlight as we think about our 2020 and -- which is why really we don't want to get into more detail on what our expectations are at this stage.

    就製造與品質而言,我們高度聚焦的一件事,是確保高品質製造,並且在品質方面有正確的投資。而這有兩種形式:當然包括營運費用(OpEx),也包括一些資本支出(CapEx)。所以這也是我們在思考 2020 規劃時在看的另一個面向。以上是幾個重點。而我只是挑幾件事來強調,當我們思考 2020——也因此在這個階段我們確實不想對預期提供更多細節。

  • The -- as it relates to share buyback, like I say, our policy is simple and straightforward. And frankly, we really haven't varied from it over the last many years. We simply cannot comment on share buybacks until we've completed them. So you can expect...

    至於股票回購——如我所說,我們的政策簡單明確。坦白說,過去很多年我們也沒有偏離過。在完成回購之前,我們一律不評論股票回購。所以你可以預期……

  • Vijay Muniyappa Kumar - MD

    Vijay Muniyappa Kumar - MD

  • What I meant here was that, was there -- is there -- can you -- are you allowed to buy back, I guess? I wasn't asking on if you are now.

    我這裡的意思是,是否——你們是否——我想問的是,你們是否被允許回購?我不是在問你們現在是否正在回購。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. So Vijay, totally understood. But in conjunction with my comment regarding we don't comment on share buybacks, furthermore, we don't comment on our ability to buy back shares. That's just -- that's how we do it.

    是的。所以 Vijay,我完全理解。但配合我剛才關於我們不評論股票回購的說法,進一步我們也不評論我們是否有能力回購股票。這就是——我們的做法。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Vijay, this has been a policy that's been here. Independent of this investigation, we wouldn't have given you this answer no matter what, no matter what.

    Vijay,這一直是我們的政策。不論是否有這項調查,我們都會給你同樣的答案,不管怎樣、不管怎樣。

  • Operator

    Operator

  • Larry Biegelsen with Wells Fargo is on the line.

    Wells Fargo 的 Larry Biegelsen 在線上。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • One on Renal and one on Nutrition. Just, Joe, on the renal care initiative, what are the next steps there? When do you think you'll be in a position to tell us more about the impact, not just from a capital standpoint but in terms of the impact on your PD business? And just is the point-of-care PD system still a 2020 launch? And I had one follow-up.

    一題關於腎臟(Renal),一題關於營養(Nutrition)。Joe,就腎臟照護計畫而言,接下來的步驟是什麼?你們何時會有條件告訴我們更多影響,不只是資本面的影響,也包括對你們 PD 業務的影響?另外,床邊(point-of-care)PD 系統仍然是 2020 年上市嗎?我還有一個追問。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Larry, we -- all the comment -- sorry, ours and a bunch of it, over 100 comments that went into the system. I think the government -- original prediction was in November, we would hear from the HHS. It can be January. We hope as soon as possible. So as soon we hear from that, we are internally preparing several different scenarios in terms of growth rates and investments. That's why we announced the $500 million investment. But there's some stuff that we can do in the meantime to increase capacity, but we're going to have to invest money. So we are looking -- we have all these scenario planned, ready to go. We're just waiting to hear what is going to be the rule itself. Is this mandatory or voluntary? Is there -- are there any changes that will make demand go up or down? Is the population that they're experimenting with, the change in the policy, the same size that was originally conceived or differently? So there are so many variables. We are on it, and we'll be ready to talk to you folks as soon as we hear from the HHS when the rule is finalized, and we are ready to go.

    Larry,我們——所有的意見——抱歉,我們的以及其他人的,超過 100 則意見都已提交到系統裡。我想政府原本預測我們會在 11 月收到 HHS 的回覆。也可能會到 1 月。我們希望越快越好。所以一旦我們收到回覆,我們內部正在準備幾種不同情境,涵蓋成長率與投資。這也是為什麼我們宣布 5 億美元的投資。不過在此期間我們也有一些事情可以做來提升產能,但我們必須投入資金。所以我們正在看——我們已把所有情境規劃好,隨時可以啟動。我們只是等待最終規則會是什麼。這是強制還是自願?是否——是否有任何變更會讓需求上升或下降?他們正在試行的族群、政策變更的規模,是否與原先構想的相同,或有所不同?所以變數非常多。我們正在積極處理,一旦 HHS 最終定案規則、我們收到消息後,我們就會準備好與各位溝通,而且我們已準備就緒。

  • Your question on point of care. Point of care, we are continuing with the clinical trial. We have more patients enrolled. And that's a great thing for us to understand how to mix a -- how to compound a drug in somebody's home. And we've been successful in doing that. But don't get all focused on that alone. We are making investments in some very interesting early technologies, and we're very excited about it. So we're seeing some other stuff. We're being first there, getting to know. We are making investments, sitting on boards of these technology companies. We think the horizon is opening quite rapidly for innovation when it comes to treatment of patients at home. So I would say, in about 5 to 7, 8 years, this outlook how you treat patients may change. And Baxter will be there because we are in the -- embedded in a lot of this new technology that is being developed at the moment.

    您關於照護現場(point of care)的問題。在照護現場方面,我們正持續進行臨床試驗。我們已納入更多病患。這對我們而言是件很棒的事,因為有助於了解如何在病患家中混合——也就是如何調配藥物。而且我們在這方面已經成功。但不要只把注意力放在這一點上。我們也正在投資一些非常有趣的早期技術,對此我們非常興奮。因此我們也看到其他一些進展。我們率先投入,先行了解。我們正在投資,並在這些科技公司的董事會任職。我們認為,在居家治療病患方面,創新的前景正相當快速地開展。所以我會說,大約在5到7、8年內,治療病患的方式展望可能會改變。而Baxter會在其中,因為我們——深度參與並嵌入目前正在開發的許多新技術之中。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • That's very helpful. Just quickly for me on Nutrition, what's the outlook there? You talked about new products in the U.S. and Europe, 2 new products, but you talked about a 3-chamber bag, I think, outside the U.S. Do you need that in the U.S. to accelerate your growth?

    這非常有幫助。我想快速問一下營養(Nutrition)方面,那邊的展望如何?您提到在美國和歐洲有新產品,兩個新產品,但我記得您也提到在美國以外有三腔袋(3-chamber bag)。要加速成長,您在美國也需要那個嗎?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Larry, we do have product in the U.S. that will have multi-chambers. We think the U.S. is a slightly different market than the European market. The European market's a really early adopter of multi-chamber bags. We -- our multi-chamber bag in the U.S. will come at the right time. As a matter of fact, we have some very advanced plans in having the product here.

    Larry,我們在美國確實會有具多腔室的產品。我們認為美國市場與歐洲市場略有不同。歐洲市場是多腔袋的非常早期採用者。我們——在美國的多腔袋會在適當的時機推出。事實上,我們已經有相當成熟的計畫,將該產品導入這裡。

  • The thing that I want you to focus is that there are opportunities outside the U.S. that we are very concentrated right now in putting together. There's opportunities in China. There are opportunities in other parts of the world. And we are also developing and feel really good about a new multi-chamber technology that our folks in Belgium are looking in developing.

    我希望您聚焦的是:美國以外有一些機會,我們目前正非常專注地在整合推進。中國有機會。世界其他地區也有機會。同時,我們也正在開發,並且對一項新的多腔技術感到非常有信心;這是我們在比利時的團隊正在研發的。

  • So we will continue to compete well. As you know, we are market leaders in the U.S. in parenteral nutrition. And we'll continue to affirm our position by launching either multi-chamber bags, either with fish oil, olive oil, whatever we think is the best combination for the patients here.

    因此我們將持續保持良好的競爭力。如您所知,我們在美國的靜脈營養(parenteral nutrition)市場是市場領導者。我們也將透過推出多腔袋——無論是添加魚油、橄欖油,或任何我們認為對這裡病患最好的組合——來持續鞏固我們的地位。

  • Operator

    Operator

  • We have one from Matt Miksic with Crédit Suisse.

    我們接下來有一題,來自瑞士信貸(Crédit Suisse)的Matt Miksic。

  • Matthew Stephan Miksic - Senior Research Analyst

    Matthew Stephan Miksic - Senior Research Analyst

  • Just a quick one for me. I think we've covered a lot of the -- of topics. But I've been hopping back and forth between the calls, so I apologize if this was answered. But oddly, the topic is FX but not the investigation. Just to maybe, Jay, if you could, quantify maybe the impact of what looked like worse FX on some of your businesses, if they showed up more in one place than another during the quarter just in terms of dollar terms. I know that's all netted out organic growth. But any color you could provide just because it looked -- did look like it stepped up during the quarter at least relative to our estimates.

    我這邊快速問一個。我想我們已經涵蓋了很多——很多主題。但我一直在不同的電話會議之間來回切換,所以如果這題已經回答過,我先致歉。不過有點奇怪的是,主題是外匯(FX),但不是那個調查。想請教也許Jay您可以量化一下:看起來更不利的外匯對你們某些業務的影響,是否在本季於某些地方比其他地方更明顯(以美元金額來看)。我知道這些都已在有機成長(organic growth)中抵銷反映。但若能提供一些補充說明會很有幫助,因為看起來——至少相對於我們的估計——本季外匯逆風似乎加大了。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Matt, I think you can appreciate our sensitivity with respect to discussions of FX on a business line or regional basis today. So I'll refrain from answering that question, and perhaps at a future date, we can get into more detail by line, by business and so on.

    Matt,我想您可以理解,我們今天在按業務線或區域層級討論外匯(FX)時的敏感性。所以我會先不回答這個問題;也許在未來某個時間點,我們可以就各產品線、各業務等提供更詳細的說明。

  • Matthew Stephan Miksic - Senior Research Analyst

    Matthew Stephan Miksic - Senior Research Analyst

  • I understand.

    我理解。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • We definitely appreciate your understanding.

    我們非常感謝您的理解。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Catherine, I think we can wrap up the call now.

    Catherine,我想我們現在可以結束這通電話會議了。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating, and have a nice day.

    各位女士、先生,Baxter International今日的電話會議到此結束。感謝各位參與,祝您有美好的一天。